- Home
- GORV vs RLYB Comparison
GORV vs RLYB Comparison
Compare GORV & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- RLYB
- Stock Information
- Founded
- GORV 1976
- RLYB 2018
- Country
- GORV United States
- RLYB United States
- Employees
- GORV N/A
- RLYB N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- RLYB Health Care
- Exchange
- GORV Nasdaq
- RLYB Nasdaq
- Market Cap
- GORV 52.1M
- RLYB 42.7M
- IPO Year
- GORV 2015
- RLYB 2021
- Fundamental
- Price
- GORV $0.80
- RLYB $0.88
- Analyst Decision
- GORV Hold
- RLYB Buy
- Analyst Count
- GORV 2
- RLYB 6
- Target Price
- GORV $2.00
- RLYB $8.10
- AVG Volume (30 Days)
- GORV 67.0K
- RLYB 94.1K
- Earning Date
- GORV 03-07-2025
- RLYB 03-11-2025
- Dividend Yield
- GORV N/A
- RLYB N/A
- EPS Growth
- GORV N/A
- RLYB N/A
- EPS
- GORV N/A
- RLYB N/A
- Revenue
- GORV $920,774,000.00
- RLYB $598,000.00
- Revenue This Year
- GORV N/A
- RLYB N/A
- Revenue Next Year
- GORV $6.13
- RLYB N/A
- P/E Ratio
- GORV N/A
- RLYB N/A
- Revenue Growth
- GORV N/A
- RLYB N/A
- 52 Week Low
- GORV $0.75
- RLYB $0.84
- 52 Week High
- GORV $5.30
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- GORV 41.89
- RLYB 37.61
- Support Level
- GORV $0.75
- RLYB $0.89
- Resistance Level
- GORV $0.98
- RLYB $0.95
- Average True Range (ATR)
- GORV 0.08
- RLYB 0.07
- MACD
- GORV -0.00
- RLYB -0.01
- Stochastic Oscillator
- GORV 17.56
- RLYB 4.74
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.